Travere Therapeutics Inc. (TVTX) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, TVTX scores 52 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars break down as follows:

• Fundamental Cash Engine: 12 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -13% and an FCF yield of 0.33%. For a prospective investor, this indicates the business is not currently generating meaningful returns on invested capital, and the cash yield on the current market capitalization is very thin. Any upside case depends on operating improvement that the source data does not yet show as sustained.
• Whale / 13F Flow: 8 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is weak, and the source data contains no 13F holder records (see Analyst View section), so the basis for this score cannot be independently verified from the provided material.
• Insider Conviction: 10 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score is below midpoint, and no transaction-level insider data is present in the source data to confirm the drivers.
• Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, this pillar reflects a beta of 1.08 and sector sensitivity. A beta slightly above 1.0 means the stock has tended to move modestly more than the broader market, which amplifies both drawdowns and rallies in a volatile tape.
• Forensic Balance Sheet: 14 / 20. Per the Roarable RQD rating, this pillar reflects Altman Z 3.44, Piotroski F 7/9, and Debt/Equity 1.79. This is the strongest pillar, though a Debt/Equity of 1.79 signals meaningful leverage relative to equity.

Investor implications: The composite score points to weak current fundamentals. Upside drivers would require sustained improvement in operating margin (currently -12.8%) and free cash generation. Valuation tradeoffs are notable: the forward P/E of 18 is available, but trailing EPS is negative at -0.27, so earnings-based valuation depends on forward estimates not included in the source data. The strongest forensic pillar offers some comfort on solvency signals, but it does not offset weak cash returns.

Per the SEC financials, revenue rose from $145.2M in FY 2023 to $490.7M in FY 2025, and FY 2025 posted positive FCF of $15.7M after deeply negative FCF in the two prior years. Operating income remained negative in all three periods, and per the market data, operating margin is -12.8% and net margin is -5.2%. Per the Roarable RQD rating, ROIC is -13%. The Altman Z-Score is 3.44 and the Piotroski F-Score is 7/9, per the Roarable RQD rating forensic pillar. Debt/Equity is 1.79, and reported debt was $220.7M at FY 2025 against cash of $93.0M.

• What are the specific revenue drivers behind the rise from $145.2M in FY 2023 to $490.7M in FY 2025, and how much is recurring?
• What is the trailing P/E and EV/EBITDA, which the source data lists as unavailable, and how do these compare to peers?
• What are the Q3 earnings expectations referenced in the news, and what growth signals are considered mixed?
• How is the debt structure (maturities, rates, covenants) positioned given Debt/Equity of 1.79?
• Who are the institutional and insider holders, and what is the direction of their recent activity?